12.67

0.48% 0.06

After Hours: 12.66 -0.010 -0.08%

Delcath Systems Inc (DCTH)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Delcath Systems Inc stock is traded at $12.67, with a volume of 348.73K. It is up +0.48% in the last 24 hours and up +6.83% over the past month. Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.

Previous Close:

$12.61

Open:

$12.85

24h Volume:

348.73K

Relative Volume:

0.92

Market Cap:

$418.35M

Revenue:

$2.07M

Net Income/Loss:

$-47.68M

P/E Ratio:

-4.4929

EPS:

-2.82

Net Cash Flow:

$-31.31M

1W Performance:

+5.94%

1M Performance:

+6.83%

6M Performance:

+60.18%

1Y Performance:

+209.02%

1-Day Range:

$12.37

$12.85

1-Week Range:

$11.19

$12.85

52-Week Range:

$3.70

$13.30

Delcath Systems Inc Stock (DCTH) Company Profile

Name

Delcath Systems Inc

Sector

Healthcare (1174)

Industry

Medical Devices (149)

Phone

(518) 743-8892

Address

566 QUEENSBURY AVENUE, QUEENSBURY, NY

Employee

Twitter

@delcathsystems

Next Earnings Date

2024-11-08

Latest SEC Filings

DCTH's Discussions on Twitter

Compare DCTH with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
DCTH Delcath Systems Inc	12.67	418.35M	2.07M	-47.68M	-31.31M	-2.82
ABT Abbott Laboratories	113.83	197.43B	41.22B	5.77B	6.49B	3.29
SYK Stryker Corp	361.52	137.82B	21.97B	3.59B	3.21B	9.33
BSX Boston Scientific Corp	90.69	133.66B	15.91B	1.79B	1.89B	1.21
MDT Medtronic Plc	80.95	103.80B	33.00B	4.29B	5.50B	3.27
EW Edwards Lifesciences Corp	73.91	43.59B	6.60B	4.16B	490.10M	6.93

Delcath Systems Inc Stock (DCTH) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-28-24	Initiated	Craig Hallum	Buy
May-14-24	Initiated	Stephens	Overweight
Jul-26-22	Resumed	Canaccord Genuity	Buy
Dec-10-21	Initiated	H.C. Wainwright	Buy
Mar-09-21	Initiated	Canaccord Genuity	Buy
Jan-05-21	Initiated	BTIG Research	Buy
Jun-01-20	Initiated	Laidlaw	Buy

View All

Delcath Systems Inc Stock (DCTH) Latest News

Jan 03, 2025

Delcath Systems Awards 30,000 Stock Options to New Employee at $12.04 Per Share - StockTitan

Jan 03, 2025

State Street Corp Buys 9,400 Shares of Delcath Systems, Inc. (NASDAQ:DCTH) - Defense World

Jan 03, 2025

Jan 01, 2025

Delcath Systems, Inc. (NASDAQ:DCTH) Short Interest Update - MarketBeat

Jan 01, 2025

Wall Street Analysts Believe Delcath Systems (DCTH) Could Rally 96.84%: Here's is How to Trade - MSN

Jan 01, 2025

Delcath Systems raises additional USD 16.3M in funding - Medical Buyer

Jan 01, 2025

Dec 31, 2024

Delcath Systems announces additional $16.3 million in funding from warrant exercises - MSN

Dec 31, 2024

Delcath Systems (NASDAQ: DCTH) Announces Recent Funding and Warrant AmendmentsQueensbury, New York, December 30, 2024 – Delcath Systems, Inc. (NASDAQ: DCTH) recently disclosed important financial developments through an 8-K filing with th - Defense World

Dec 31, 2024

Dec 30, 2024

Delcath secures $16.3 million from warrant exercises By Investing.com - Investing.com Nigeria

Dec 30, 2024

Delcath Systems Secures $16.3 Million in Funding Through Warrant Exercise to Propel Growth in Oncology Treatments - Tandav Media

Dec 30, 2024

Delcath secures $16.3 million from warrant exercises - Investing.com India

Dec 30, 2024

Delcath Systems Secures $16.3M from Warrant Exercise - TipRanks

Dec 30, 2024

Delcath Systems Raises $16.3M Through Warrant Exercise to Advance HEPZATO Melanoma Treatment - StockTitan

Dec 30, 2024

3 US Growth Companies To Watch With Up To 32% Insider Ownership - Simply Wall St

Dec 30, 2024

Dec 29, 2024

(DCTH) Technical Data - Stock Traders Daily

Dec 29, 2024

Analysts Expect Breakeven For Delcath Systems, Inc. (NASDAQ:DCTH) Before Long - Yahoo Finance

Dec 29, 2024

Dec 19, 2024

Does Delcath Systems (NASDAQ:DCTH) Have A Healthy Balance Sheet? - Simply Wall St

Dec 19, 2024

Where are the Opportunities in (DCTH) - Stock Traders Daily

Dec 19, 2024

Dec 16, 2024

Delcath Systems stock soars to 52-week high of $12.99 - Investing.com

Dec 16, 2024

Dec 15, 2024

Positive Preliminary Results from Delcath Systems’ FOCUS Trial Presented at the 2021 ASCO Annual Meeting - Marketscreener.com

Dec 15, 2024

Dec 13, 2024

Clear Street initiates Buy on Delcath Systems stock, highlights profitability potential - Investing.com

Dec 13, 2024

Dec 10, 2024

Thinking about buying stock in Nikola, Delcath Systems, Taysha G - GuruFocus.com

Dec 10, 2024

Dec 09, 2024

Uveal melanoma Treatment Market: Segmentation Trends, - openPR

Dec 09, 2024

Dec 08, 2024

When (DCTH) Moves Investors should Listen - Stock Traders Daily

Dec 08, 2024

Dec 06, 2024

Polar Asset Management Partners Inc. Purchases New Position in Delcath Systems, Inc. (NASDAQ:DCTH) - MarketBeat

Dec 06, 2024

Dec 03, 2024

Delcath to trial Hepzato drug device combo in colorectal cancer - Yahoo Finance

Dec 03, 2024

Dec 02, 2024

FDA finishes review of Delcath’s IND application of HEPZATO combo trial - TipRanks

Dec 02, 2024

Delcath Secures FDA Clearance for Phase 2 Trial of HEPZATO in Colorectal Cancer - StockTitan

Dec 02, 2024

Delcath Systems (NASDAQ:DCTH) jumps 13% this week, taking one-year gains to 330% - Yahoo Finance

Dec 02, 2024

Nov 29, 2024